ホーム › びまん性大細胞型B細胞リンパ腫 › イリノイ州 › Chicago
Chicago、ILにおけるびまん性大細胞型B細胞リンパ腫の臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、びまん性大細胞型B細胞リンパ腫に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
被験者募集中第2相
- Northwestern University, Chicago
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
被験者募集中第2相
- University of Chicago Medical Center ( Site 0126), Chicago
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
被験者募集中第1相
- The University of Chicago Medical Center (UCMC), Chicago
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
被験者募集中第1相
- University of Chicago Comprehensive Cancer Center, Chicago
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
被験者募集中第2相
- Northwestern University - Feinberg School of Medicine, Chicago
- Rush University Medical Center, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
被験者募集中第1/2相
- University of Chicago, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
被験者募集中観察研究
- Robert H Lurie Cancer Center, Chicago
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
被験者募集中第3相
- Northwestern, Chicago
- University of Chicago, Chicago
DALY II USA/ MB-CART2019.1 for DLBCL
被験者募集中第2相
- Robert H Lurie Cancer Center, Chicago
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
被験者募集中第1相
- University of Illinois at Chicago, Chicago
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
被験者募集中第1相
- Northwestern University, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- Northwestern University, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
被験者募集中第1/2相
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- The University of Chicago Medical Center, Chicago
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
被験者募集中第2相
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
被験者募集中第2相
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
被験者募集中第1相
- University of Chicago, Chicago
他の都市におけるびまん性大細胞型B細胞リンパ腫の試験
- New York City, NY21件の研究
- Baldwin Park, CA19件の研究
- Houston, TX17件の研究
- Los Angeles, CA17件の研究
- Boston, MA16件の研究
- Milwaukee, WI16件の研究
- Philadelphia, PA15件の研究
- Portland, OR15件の研究
- Durham, NC14件の研究
- Nashville, TN14件の研究
- Dallas, TX13件の研究
- Salt Lake City, UT12件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん58件の研究
- がん（全種類）51件の研究
- 前立腺がん45件の研究
- 転移性癌45件の研究
- 肥満症42件の研究
- 肺がん41件の研究
- 卵巣がん36件の研究
- 脳卒中34件の研究
- 大腸癌32件の研究
- 心不全31件の研究
- 過体重28件の研究
ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。